心肌梗死后使用 β 受体阻滞剂：ABYSS 是否证实了 REDUCEd 的使用？

IF 41.7 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Nature Reviews Cardiology Pub Date : 2024-10-09 DOI:10.1038/s41569-024-01093-z

Robin Hofmann, Stefan James

{"title":"心肌梗死后使用 β 受体阻滞剂：ABYSS 是否证实了 REDUCEd 的使用？","authors":"Robin Hofmann, Stefan James","doi":"10.1038/s41569-024-01093-z","DOIUrl":null,"url":null,"abstract":"In contrast to the ABYSS investigators’ interpretation of the primary results of their trial, we believe that β-blockers can be safely discontinued in the majority of patients after an uncomplicated myocardial infarction. However, in individuals developing symptoms of angina or heart failure, β-blocker treatment remains one of several guideline-recommended therapies.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":"22 1","pages":"7-8"},"PeriodicalIF":41.7000,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"β-blockers after MI: does ABYSS confirm REDUCEd use after all?\",\"authors\":\"Robin Hofmann, Stefan James\",\"doi\":\"10.1038/s41569-024-01093-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In contrast to the ABYSS investigators’ interpretation of the primary results of their trial, we believe that β-blockers can be safely discontinued in the majority of patients after an uncomplicated myocardial infarction. However, in individuals developing symptoms of angina or heart failure, β-blocker treatment remains one of several guideline-recommended therapies.\",\"PeriodicalId\":18976,\"journal\":{\"name\":\"Nature Reviews Cardiology\",\"volume\":\"22 1\",\"pages\":\"7-8\"},\"PeriodicalIF\":41.7000,\"publicationDate\":\"2024-10-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Cardiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/s41569-024-01093-z\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Cardiology","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41569-024-01093-z","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

与 ABYSS 研究人员对其试验主要结果的解释不同，我们认为大多数患者在无并发症的心肌梗死后可以安全地停用 β 受体阻滞剂。不过，对于出现心绞痛或心力衰竭症状的患者，β 受体阻滞剂治疗仍是指南推荐的几种疗法之一。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

β-blockers after MI: does ABYSS confirm REDUCEd use after all?

In contrast to the ABYSS investigators’ interpretation of the primary results of their trial, we believe that β-blockers can be safely discontinued in the majority of patients after an uncomplicated myocardial infarction. However, in individuals developing symptoms of angina or heart failure, β-blocker treatment remains one of several guideline-recommended therapies.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews Cardiology 医学-心血管系统

CiteScore

53.10

自引率

0.60%

发文量

143

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Cardiology aims to be the go-to source for reviews and commentaries in the scientific and clinical communities it serves. Focused on providing authoritative and accessible articles enriched with clear figures and tables, the journal strives to offer unparalleled service to authors, referees, and readers, maximizing the usefulness and impact of each publication. It covers a broad range of content types, including Research Highlights, Comments, News & Views, Reviews, Consensus Statements, and Perspectives, catering to practising cardiologists and cardiovascular research scientists. Authored by renowned clinicians, academics, and researchers, the content targets readers in the biological and medical sciences, ensuring accessibility across various disciplines. In-depth Reviews offer up-to-date information, while Consensus Statements provide evidence-based recommendations. Perspectives and News & Views present topical discussions and opinions, and the Research Highlights section filters primary research from cardiovascular and general medical journals. As part of the Nature Reviews portfolio, Nature Reviews Cardiology maintains high standards and a wide reach.